5 December 2017 in Diabetes
BNN27, a C17-spiroepoxy derivative of DHEA, was shown to have anti-apoptotic properties via mechanisms involving the NGF receptors (TrkA/ p75NTR). In this study we examined the effects of BNN27 on neural/glial cell function, apoptosis and inflammation in the experimental rat streptozotocin (STZ)-model of diabetic retinopathy (DR). The ability of BNN27 to activate the TrkA receptor and regulate p75NTR expression was investigated. BNN27 (2,10,50mg/kg,7days,i.p.) administration four weeks post STZ-injection (Paradigm A) reversed the diabetes-induced glial activation, loss of function of amacrine cells (bNOS/TH expression) and ganglion cell axons via a TrkAR-dependent mechanism. BNN27 activated/phosphorylated the TrkAY490 residue in the absence but not the presence of TrkAR inhibitor and abolished the diabetes-induced increase in p75NTR expression. However, it had no effect on retinal cell death (TUNEL+ cells). A similar result was observed when BNN27(10mg/kg,i.p.) was administered at the onset of diabetes, every other day for four weeks (Paradigm B). However, BNN27 decreased the activation of caspase-3 in both paradigms. Finally, BNN27 reduced the pro-inflammatory (TNFα,IL1β) and increased the anti-inflammatory (IL-10,IL-4) cytokine levels. These findings suggest that BNN27 has the pharmacological profile of a therapeutic for diabetic retinopathy, since it targets both the neurodegenerative and inflammatory components of the disease.
12 January 2005 in Naunyn-Schmiedeberg's Archives of Pharmacology
31 May 2004 in Journal of Hepatology
1 May 2004 in Investigative Ophthalmology & Visual Science
Purpose. To investigate the presence of somatostatin and its receptors (sst1–5 receptors) and their possible involvement in the regulation of nitric oxide (NO) production in human RPE cell cultures. methods. Human RPE cells (D407) were used for all studies performed. Somatostatin levels were detected by radioimmunoassay, and RT-PCR and immunocytochemistry studies were performed to identify the somatostatin receptors (sst1-sst5). Radioligand binding assays were also performed examining the ability of certain somatostatin ligands (sst1, sst2, sst5) to compete for [125I]Tyr11 somatostatin binding. The presence of NO synthase in the cultures was assayed with NADPH-diaphorase cytochemistry, and RT-PCR, and NO levels were assessed by examining the production of its stable metabolites NO2 − and NO3 − (NOx −). results. SRIF was detected in a concentration of 0.56 ± 0.13 picomoles/mg protein. sst1, sst2, and sst5 mRNAs were detected, yet only sst2B and sst5 immunoreactivity was observed in human RPE cell cultures. sst1- and sst5- but not sst2-selective ligands displaced the specific [125I]Tyr11 somatostatin binding to RPE cell membranes. NADPH-diaphorase stain and iNOS mRNA were detected. SRIF and the sst2-selective analogue MK678 increased the levels of NOx − in a concentration-dependent manner. This increase was blocked by the sst2 antagonist CYN-154806 (Ac-4NO2-Phe-c(dCys-Tyr-dTrp-Lys-Thr-Cys)-dTyr-NH2). conclusions. These results demonstrate the presence of somatostatin, and its receptors sst1, sst2B, and sst5 in human RPE cells and suggest an autocrine or paracrine role for somatostatin. Somatostatin’s ability to regulate NO production, by activating sst2 receptors, provides a functional role of somatostatin in the RPE.
1 January 2006 in Regulatory Peptides
1 February 2004 in Neuroscience Letters